Novartis halts CAR-T trials after three patient deaths from an immune overreaction; Bristol Myers pauses zola-cel enrollment.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results